

Human APLNR VLP

Cat. No. APL-HM0P112



Description

Source	Recombinant Human APLNR VLP is expressed from HEK293. It contains Met1-Asp380 (It may have cross reaction with anti-His antibody).
Accession	P35414
Molecular Weight	The target protein has a predicted MW of 46.7 kDa.
Endotoxin	Less than 1 EU per µg by the LAL method.
Purity	> 95% as determined by HPLC

Formulation and Storage


Formulation	Supplied as 0.22µm filtered solution in PBS, 200mM L-arginine (pH 7.4). Notice: If you need it for immunization, water-soluble adjuvant is recommended.
Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Apelin receptor (APJ), a member of the class A family of G protein-coupled receptor (GPCR), plays a crucial role in regulating cardiovascular and central nervous systems function. APJ influences the onset and progression of various diseases such as hypertension, atherosclerosis, and cerebral stroke, making it an important target for drug development.

Assay Data

SEC-HPLC




The purity of Human APLNR VLP is greater than 95% as determined by SEC-HPLC.

ELISA Data

Assay Data

Human APLNR VLP ELISA
0.5µg Human APLNR VLP Per Well



Immobilized Human APLNR VLP at 5µg/ml (100µl/well) on the plate. Dose response curve for Anti-APLNR Antibody, hFc Tag with the EC50 of 0.20µg/ml determined by ELISA (QC Test).